UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment

NCT02499081 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Ixazomib

Sponsor

University of Arkansas

Collaborators

[object Object]